MedTech Strategist Issue: Vol. 5, No. 8 - June 8, 2018
Already a Subscriber?
Not a Subscriber?
"Managing in Interesting Times: An Interview with Paul LaViolette"
By David Cassak, Co-Editor-in-Chief
Over a career that has spanned nearly 40 years, Paul LaViolette has been at the center of some of the most interesting episodes in the medtech industry’s history. From consolidation to the current state of medtech investing, arguably no executive has experienced more of the dynamics roiling the industry today.
Value Assessment Tools: "In Medtech, Real-World Evidence is Moving Beyond Theory to Regulatory Use"
By Wendy Diller, Senior Writer/Market Analyst
This year’s annual meeting of ISPOR highlighted efforts to incorporate RWE as a standard tool in regulatory evaluation of medical devices, aided by the rapid digitization of healthcare data and its tremendous potential to reset how FDA calculates risk in assessing device innovation.
Digital Health Strategies: "ResMed: Using Digital Health to Fuel a Medtech Growth Strategy"
By Mary Stuart, Senior Writer/Market Analyst
Sleep apnea market leader ResMed has moved beyond a product business driven by incremental advances around CPAP machines and masks to become a software-driven company. Jim Hollingshead, president of ResMed’s Sleep Business and an early architect of the company’s digital health strategy, discusses how ResMed’s connected solutions are helping its customers to be more efficient and profitable, keeping more patients on therapy, and increasing its own market share.
Marketing Strategies: "Digital Innovation: Consumer Activation Comes of Age in Medtech"
By Ajay Gupta, Karen Passmore, Sundar Ganapathy, and Chris Smith
Digital innovation is opening the door for savvy medical device companies to leverage affordable multi-channel and dual push-pull strategies to reach patients directly to drive market adoption and sales growth.
Executive Interview: "What’s Next for the Ischemic Stroke Market? Brett Wall, SVP and President of Brain Therapies at Medtronic, Weighs In"
By Mary Thompson, Executive Editor
New data documenting the benefits of endovascular clot removal for ischemic stroke, even in patients who present as late as 24-hours after stroke onset, have opened up endovascular thrombectomy to a much larger patient pool and raised the stakes for companies targeting this space. Even so, as Brett Wall, SVP and President of Brain Therapies at Medtronic, points out in this Q&A, competitors would be well-advised to take a page from Medtronic and keep a close eye on new opportunities and innovations in this fast-moving field.
Start-Ups To Watch - Ophthalmology: "Eyenuk: Artificial intelligence Boosts Diabetic Retinopathy Screening Rates"
By Mary Stuart, Senior Writer/Market Analyst
Diabetes risks creating an epidemic of blindness, since 40% of people with diabetes develop retinopathy. Only about half of diabetes patients comply with annual eye screening recommendations, a gap Eyenuk thinks it can bridge by putting expert software for evaluating the back of the eye into the hands of primary care and other frontline physicians that care for patients with diabetes.
Start-Ups To Watch - Cardiology: "HeartSciences: Artificial Intelligence Improves Frontline Risk Stratification for Heart Diseases"
By Mary Stuart, Senior Writer/Market Analyst
The current screening paradigm for heart disease is missing people at early stages, when diseases are most treatable. HeartSciences has taken a ubiquitous screening tool, the 12-lead ECG, and has, through the application of signal processing and artificial intelligence, turned it into a powerful tool that can detect diastolic dysfunction, an early indicator of most cardiac diseases.
Not a Subscriber?
Already a Subscriber?
Want a Sample Article?
Companies Covered in this Issue: Abbott Laboratories Inc., Boston Scientific Corp., CR Bard Inc., Cochlear Ltd., ConforMIS Inc., Depuy Synthes, Eyenuk Inc., EyePACS LLC, Fisher & Paykel Healthcare Ltd., General Electric Co., HeartSciences Inc., IDx LLC, General Electric Co., Johnson & Johnson, Medtronic PLC, Nuvasive Inc., Penumbra Inc., Philips Respironics, ResMed Inc., Retmarker Ltd., Royal Philips Electronics NV, SonaCare Medical LLC, Zimmer Biomet Holdings Inc., Stryker Corp.
Topics Covered in this Issue: Cardiovascular/Vascular, Diabetes, Executive Interviews, Investment/Finance/M&As, Health Information Technology/Digital Health, Healthcare Delivery/Providers/Payors, Imaging, Medtech Business Strategies/Development, Neurology/Neurovascular, Ophthalmology, Reimbursement/Regulatory, Respiratory, Start-Ups
